Page 190 - 2020_11-Haematologica-web

2678
Letters to the Editor
Yucai Wang,1 Kari G. Rabe,2 Michael S. Bold,3 Min Shi,4 Curtis A. Hanson,4 Susan M. Schwager,1 Timothy G. Call,1 SaadS.Kenderian,1 EliMuchtar,1 SuzanneR.Hayman,1 Amber B. Koehler,1 Amie L. Fonder,1 Asher A. Chanan-Khan,5 Daniel L. Van Dyke,6 Susan L. Slager,2 Neil E. Kay,1
Wei Ding,1 Jose F. Leis7 and Sameer A. Parikh1
1Division of Hematology, Mayo Clinic, Rochester, MN; 2Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; 3Department of Radiology, Mayo Clinic, Rochester, MN; 4Division
of Hematopathology, Mayo Clinic, Rochester, MN; 5Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL; 6Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN and 7Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA
Correspondence:
SAMEER A. PARIKH - parikh.sameer@mayo.edu
Funding: SSK and SAP are recipients of the K12 CA090628 grant from the National Cancer Institute (Paul Calabresi Career Development Award for Clinical Oncology).
doi:10.3324/haematol.2019.240564
References
1. ParikhSA,KayNE,ShanafeltTD.HowwetreatRichtersyndrome. Blood. 2014;123(11):1647-1657.
2. Rossi D, Gaidano G. Richter syndrome: pathogenesis and manage- ment. Semin Oncol. 2016;43(2):311-319.
3. RossiD,SpinaV,GaidanoG.BiologyandtreatmentofRichtersyn- drome. Blood. 2018;131(25):2761-2772.
4. Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center. Haematologica. 2020;105(3):765-773.
5. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of
Richter's transformation of chronic lymphocytic leukemia by
PET/CT. J Nucl Med. 2006;47(8):1267-1273.
6. MauroFR,ChauvieS,PaoloniF,etal.Diagnosticandprognosticrole
of PET/CT in patients with chronic lymphocytic leukemia and pro-
gressive disease. Leukemia. 2015;29(6):1360-1365.
7. Falchi L, Keating MJ, Marom EM, et al. Correlation between
FDG/PET, histology, characteristics, and survival in 332 patients with
chronic lymphoid leukemia. Blood. 2014;123(18):2783-2790.
8.. Michallet AS, Sesques P, Rabe KG, et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's syndrome. Leuk Lymphoma. 2016;57(6):1474-
1477.
9. JainP,KeatingM,WierdaW,etal.Outcomesofpatientswithchron-
ic lymphocytic leukemia after discontinuing ibrutinib. Blood.
2015;125(13):2062-2067.
10. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib
therapy discontinuation and outcomes in patients with chronic lym-
phocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
11. Jain P, Thompson PA, Keating M, et al. Long-term outcomes for
patients with chronic lymphocytic leukemia who discontinue ibruti-
nib. Cancer. 2017;123(12):2268-2273.
12. Mato AR, Wierda WG, Davids MS, et al. Utility of PET-CT in
patients with chronic lymphocytic leukemia following B-cell recep- tor pathway inhibitor therapy. Haematologica. 2019;104(11):2258- 2264.
13. Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774-782.
14. Galicia-VazquezG,SmithS,AloyzR.Del11q-positiveCLLlympho- cytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018; 8(1):13.
15. Galicia-Vazquez G, Aloyz R. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? Crit Rev Oncol Hematol. 2019;134:65-70.
haematologica | 2020; 105(11)